Letter From the Editor
Letter From the Editor: Addressing the Racial Gap in Health Care
Feature Article
Neoadjuvant Therapies in High-Risk Localized Prostate Cancer: Past, Present, and Future
Abstract: Treatment for high-risk localized prostate cancer can be particularly challenging because of an elevated risk of disease recurrence. One of the proposed ways to improve […]
From Recent Issues
Feature Article
Neoadjuvant Therapies in High-Risk Localized Prostate Cancer: Past, Present, and Future
Abstract: Treatment for high-risk localized prostate cancer can be particularly challenging because of an elevated risk of disease recurrence. One of the proposed ways to improve […]
Feature Article
Artificial Intelligence in Prostate Cancer Diagnosis and Management: State-of-the-Art Approaches and Emerging Innovations
Abstract: Artificial intelligence (AI) is rapidly changing the field of medicine, and prostate cancer is no exception. The significant heterogeneity that characterizes the natural history of […]
Feature Article
Clinical Applications of PARP Inhibitors in Breast, Ovarian, and Prostate Cancer: Current Insights and Future Directions
Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)–deficient cancers, especially those with BRCA1/2 mutations. Since […]
Supplements
Redefining Second-Line Treatment Strategy, Sequencing, and Real-World Implementation in Relapsed/Refractory Multiple Myeloma: Insights From the 31st Annual Congress of the European Hematology Association
Abstract: The management of relapsed/refractory (R/R) multiple myeloma (MM) continues to evolve with the introduction of novel therapies and the use of newer therapies in different treatment […]
Case Study Series
PNH Management: A Clinical Case of Ravulizumab–Danicopan Combination Therapy
About the Patient Patient EW is a 56-year-old woman who was diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) 9 years ago, at the age of 47. At […]
Molecular Residual Disease (MRD) Testing: Advancing Clinical Decision-Making in Breast Cancer
Abstract: Circulating tumor DNA (ctDNA) is emerging as a clinically meaningful biomarker across multiple solid tumors, including breast cancer. Advances in personalized, tumor-informed whole-genome sequencing have enabled […]